Featured publications

• Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

  Gimenez, Neus; Schulz, Ralph; Higashi, Morihiro; Aymerich, Marta; Villamor, Neus;

  (...)

  Lopez-Guerra, Monica; Campo, Elias; Rosich, Laia; Seiffert, Martina; Colomer, Dolors.

  See complete list of authors

  Reference:

  Leukemia 2020.

• Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

  Lee-Verges, Eriong; Hanna, Bola S; Yazdanparast, Haniyeh; Rodriguez, Vanina; Leonor Rodriguez, Marta;

  (...)

  Perez-Galan, Patricia; Lopez-Guerra, Monica; Campo, Elias; Seiffert, Martina; Colomer, Dolors.

  See complete list of authors

  Reference:

  International Journal Of Cancer 2019.

• Control of chronic lymphocytic leukemia development by clonally-expanded CD8+T-cells that undergo functional exhaustion in secondary lymphoid tissues

  Hanna B; Roessner P; Yazdanparast H; Colomer D; Campo E;

  (...)

  Stilgenbauer S; Schmidt M; Gabriel R; Lichter P; Seiffert M.

  See complete list of authors

  Reference:

  Leukemia 2019.

• Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

  Gimenez, Neus; Martinez-Trillos, Alejandra; Montraveta, Arnau; Lopez-Guerra, Monica; Rosich, Laia;

  (...)

  Lopez-Otin, Carlos; Lopez-Guillermo, Armando; Campo, Elias; Colomer, Dolors; Villamor, Neus.

  See complete list of authors

  Reference:

  Haematologica 2019.

• The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

  Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;

  (...)

  Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.

  See complete list of authors

  Reference:

  Haematologica 2017.

• The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

  Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;

  (...)

  Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.

  See complete list of authors

  Reference:

  Clinical Cancer Research 2017.

• New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.

  Tripathi R; Lee-Verges E; Higashi M; Gimenez N; Rosich L;

  Lopez-Guerra M; Colomer D .

  Reference:

  Expert Opinion On Drug Discovery 2017.

• The gamma-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells

  Lopez-Guerra, M; Xargay-Torrent, S; Rosich, L; Montraveta, A; Roldan, J;

  (...)

  Lopez-Otin, C; Perez-Galan, P; Roue, G; Campo, E; Colomer, D.

  See complete list of authors

  Reference:

  Leukemia 2015.

• Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

  Martinez-Trillos, Alejandra; Pinyol, Magda; Navarro, Alba; Aymerich, Marta; Jares, Pedro;

  (...)

  Rozman, Ciril; Lopez-Otin, Carlos; Campo, Elias; Lopez-Guillermo, Armando; Villamor, Neus.

  See complete list of authors

  Reference:

  Blood 2014.

• NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

  Villamor, N; Conde, L; Martinez-Trillos, A; Cazorla, M; Navarro, A;

  (...)

  Lopez-Otin, C; Jares, P; Pereira, A; Campo, E; Lopez-Guillermo, A.

  See complete list of authors

  Reference:

  Leukemia 2013.